Artiva Biotherapeutics Inc (ARTV) Quarterly Institutional 13F Update (Q2 2026)

ARTV ranks #5243 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

ARTV is a disclosed holding of Andreas Halvorsen (Viking Global Investors), one of the tracked superinvestors on AlphaSMO — it makes up 0.1% of that fund's own 13F portfolio.

ARTV is a top-conviction position for 5AM Venture Management, LLC — at 7.9% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in ARTV belongs to Ra Capital Management, L.p., but the position matters far more to 5AM Venture Management, LLC, who has 7.9% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Ra Capital Management, L.p. has added to its ARTV position for two straight quarters, increasing it by $131.9M to reach $174.2M today.

Morgan Stanley has trimmed its ARTV position for two straight quarters, cutting it by $94.7K while still holding $21.5K.

ARTV is up 0.3% today, and institutions have been net buyers of $235.8M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ARTV reported a net loss of $90.8M over the trailing twelve months.

• Not yet profitable — net loss of $90.8M over the trailing twelve months
• Net income declined year over year, from -$75.1M to -$90.8M
• Operating cash flow was negative, using $76.8M in cash
• Current ratio of 8.61x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.19x equity — within a conventional range